Raise closed, search for fresh raises on Seedstage

Woburn, MA

Developing advanced bioconjugates to improve the safety and effectiveness of cancer treatments.

• Mission: CellMosaic is focused on advancing bioconjugate solutions, particularly antibody-drug conjugates (ADCs), using its proprietary AqueaTether (AqT) technology to improve the safety and effectiveness of cancer therapies.
    
• Innovation: The company’s AqT technology addresses critical challenges in drug development, such as hydrophobicity and toxicity, that often limit the therapeutic potential of ADCs. This technology aims to create more stable, safer, and effective bioconjugates for cancer treatment.
    

• Market Opportunity: CellMosaic seeks to tap into the rapidly growing ADC market, which holds significant promise in oncology and is expected to become a key therapeutic approach for cancer treatment. The company plans to license its technology to biopharmaceutical companies, expanding its reach and application.

• Product Offering: CellMosaic develops custom kits and bioconjugates for use in the global biotech market, focusing on scaling production and R&D to create more accessible ADC treatments. Its solutions are designed to enhance the performance of cancer drugs, improving efficacy and reducing side effects.

• Growth Strategy: The funds raised will support scaling production, expanding R&D capabilities, and forming strategic partnerships and licensing agreements for its AqT technology. This strategy positions CellMosaic to capture a share of the growing global market for ADCs.

• Impact: By addressing the challenges in current ADC therapies, CellMosaic aims to transform cancer treatment by providing safer, more accessible options that could potentially improve patient outcomes and reduce toxicity.

CellMosaic is a biotechnology company with a focus on advancing bioconjugate solutions, particularly antibody-drug conjugates (ADCs), through its proprietary AqueaTether (AqT) technology. Founded in 2008, the company leverages 15 years of expertise to develop and commercialize advanced bioconjugates, including kits and custom services, for the global biotech market. Operating from its U.S. facility, CellMosaic addresses the challenges of bioconjugation, such as drug hydrophobicity and toxicity, providing solutions to enhance the safety and efficacy of therapies like ADCs.

This fundraising initiative is aimed at expanding CellMosaic’s bioconjugate capabilities, focusing on strategic partnerships and licensing AqT technology to biopharmaceutical companies for ADC development. The funds will support scaling production and R&D for innovative AqT-linked bioconjugates, aiming to position ADCs as safer, more accessible treatments, potentially transforming cancer therapy. By addressing market demands for high-quality and stable bioconjugates, CellMosaic seeks to enhance its role in the growing ADC market, projected to reach significant market value in the coming years.

Company Info

Developing advanced bioconjugates to improve the safety and effectiveness of cancer treatments.

CellMosaic is a biotechnology company with a focus on advancing bioconjugate solutions, particularly antibody-drug conjugates (ADCs), through its proprietary AqueaTether (AqT) technology. Founded in 2008, the company leverages 15 years of expertise to develop and commercialize advanced bioconjugates, including kits and custom services, for the global biotech market. Operating from its U.S. facility, CellMosaic addresses the challenges of bioconjugation, such as drug hydrophobicity and toxicity, providing solutions to enhance the safety and efficacy of therapies like ADCs.

This fundraising initiative is aimed at expanding CellMosaic’s bioconjugate capabilities, focusing on strategic partnerships and licensing AqT technology to biopharmaceutical companies for ADC development. The funds will support scaling production and R&D for innovative AqT-linked bioconjugates, aiming to position ADCs as safer, more accessible treatments, potentially transforming cancer therapy. By addressing market demands for high-quality and stable bioconjugates, CellMosaic seeks to enhance its role in the growing ADC market, projected to reach significant market value in the coming years.